This application is for the competitive renewal of the Digestive Disease Research Core Center (DDRCC) at the University of Chicago. This Center's major theme is the study of the biology and pathobiology of epithelial cells of the gastrointestinal tract. This DDRCC will continue to be a multidisciplinary and cooperative endeavor involving 58 investigators (29 full members and 29 associate members) in the clinical and basic science departments of the Division of Biological Sciences at the University of Chicago.
The aims of this DDRCC have not changed and are: 1) to foster digestive diseases-related research in a supportive, integrative, collaborative and multidisciplinary manner; 2) to enhance the basic research capabilities of established digestive diseases investigators; 3) to encourage investigators not involved in digestive diseases-related research to become interested in pursuing problems related to this important area of investigation; 4) to develop and implement programs for training and establishment of young investigators in digestive diseases- related research; 5) to facilitate the transfer of new research findings to the clinical area; and 6) to inform others in both professional and lay settings of the accomplishments, opportunities and advances in digestive disease-related research. The DDRCC at the University of Chicago has three core laboratories (Cell Biology, Molecular Biology, and Biochemistry and Biophysics) to foster digestive diseases-related research, Pilot and Feasibility Studies and New Investigator Award programs to foster participation of younger and established investigators in research related to digestive diseases and an Administrative Core to oversee the operation of the Center as a whole. Taken together, these objectives and components define the University of Chicago's DDRCC.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK042086-09
Application #
2838113
Study Section
Special Emphasis Panel (SRC (21))
Program Officer
Podskalny, Judith M,
Project Start
1990-01-01
Project End
2000-11-30
Budget Start
1999-03-15
Budget End
1999-11-30
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Amin, Ruhul; Asplin, John; Jung, Daniel et al. (2018) Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria. Kidney Int 93:1098-1107
Miyoshi, Jun; Nobutani, Kentaro; Musch, Mark W et al. (2018) Time-, Sex-, and Dose-Dependent Alterations of the Gut Microbiota by Consumption of Dietary Daikenchuto (TU-100). Evid Based Complement Alternat Med 2018:7415975
Lu, Jing; Lu, Lei; Yu, Yueyue et al. (2018) Effects of Intestinal Microbiota on Brain Development in Humanized Gnotobiotic Mice. Sci Rep 8:5443
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Chen, Edmund B; Cason, Cori; Gilbert, Jack A et al. (2018) Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. J Gastrointest Surg 22:1112-1123
Chew, Justin; Leypunskiy, Eugene; Lin, Jenny et al. (2018) High protein copy number is required to suppress stochasticity in the cyanobacterial circadian clock. Nat Commun 9:3004
Ruderman, Sarah; Eshein, Adam; Valuckaite, Vesta et al. (2018) Early increase in blood supply (EIBS) is associated with tumor risk in the Azoxymethane model of colon cancer. BMC Cancer 18:814
Dugas, Lara R; Lie, Louise; Plange-Rhule, Jacob et al. (2018) Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol. BMC Public Health 18:978
McIntosh, Christine M; Chen, Luqiu; Shaiber, Alon et al. (2018) Gut microbes contribute to variation in solid organ transplant outcomes in mice. Microbiome 6:96
Overstreet, A M; LaTorre, D L; Abernathy-Close, L et al. (2018) The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis. Mucosal Immunol 11:1454-1465

Showing the most recent 10 out of 697 publications